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The coronavirus who that causes Covid-19 first appeared in Wuhan Distric, China, in December 2019, and has 
been a pandemic to date. In addition to the increasing prevalence of Covid-19 deaths, there are also several Covid-19 
patients who have recovered. As we know that until now there is no single drug specifically for the treatment of Covid-19, 
so the reuse of available drugs is still carried out as an alternative. However, all these alternative medicines are still in 
the form of trial and error until now. The purpose of the research in this study is to find out what drugs have become 
alternatives for therapy in current Covid-19 patients. The method used in this research is literature study by collecting 
data from various scientific journals through various databases. From this research, after reviewing 12 journals. Drugs 
used as alternative treatments for Covid-19 patients that have been scientifically proven based on several literature studies 
include, Favipiravir, Remdesivir, Azithromycin, Levofloxacin, and several supporting nutrients namely Vitamin C, Vitamin 
E and Vitamin D. 
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ABSTRAK 
Coronavirus yang menyebabkan Covid-19 pertama kali muncul di wilayah Wuhan, China, pada Desember 2019, 
dan telah menjadi pandemi hingga saat ini. Disamping pravalensi kematian kasus Covid-19 yang terus meningkat, terdapat 
pula beberapa pasien Covid-19 yang sembuh. Seperti yang kita ketahui bahwa hingga detik ini belum ada satupun obat 
yang dikhususkan untuk pengobatan Covid-19, sehingga penggunaan kembali obat-obat yang tersedia masih dilakukan 
sebagai alternatif. Namun, semua obat-obat alternatif tersebut masih berupa trial and error hingga saat ini. Tujuan 
penelitiam dalam pengkajian ini adalah untuk memperoleh data tentang obat-obat apa saja yang telah menjadi alternatif 
untuk terapi pada pasien Covid-19 saat ini. Metode yang digunakan pada penelitian ini yaitu studi literatur dengan 
mengumpulkan data dari berbagai jurnal ilmiah melalui berbagai database. Dari penelitian ini, setelah dilakukan pengkajian 
terhadap beberapa jurnal, obat-obat yang digunakan sebagai alternatif pengobatan pada pasien Covid-19 yang telah terbukti 
secara ilmiah berdasarkan beberapa studi literatur antara lain, Favipiravir, Remdesivir, Azitromisin, Levofloksasin, dan 
beberapa  nutrisi penunjang yakni Vitamin C, Vitamin E dan Vitamin D. 




At Desember 2019, in Wuhan Distric of 
China, the first death caused by a virus from a 
new strain of the Coronavirus family was 
reported as Severe Acute Respiratory 
Syndrome Coronavirus-2 (SARS-CoV-2), and 
the disease caused by the virus is called 
Coronavirus Disease. The disease, also known 
as Coronavirus Infection Disease 2019 or 
Covid-19, is an infectious disease of the 
respiratory tract carried by the Novel 
Coronavirus (Pawar, 2020). 
WHO declares that corona disease is a 
Public Health Emergency, it was reported that 
Covid-19 had penetrated as many as 219 
countries with the number of confirmed cases 
as many as 49,242,837 and deaths reaching 
1,242,187 with the number of patients 
increasing every time. Indonesia is ranked 15th 
in the highest number of deaths in the world, 
with 438,716 people who have been confirmed 
positive for Covid-19 (World Health 
Organization, 2020). As time goes by, the 
clinical spectrum of Covid-19 disease is getting 
wider, some cases are getting more complicated 
to be handled by medical personnel, especially 
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by doctors, so they are also required to be really 
careful and precise in diagnosing a disease and 
accompanied by giving treatment of patients as 
much as possible. 
In Covid-19 patients with a fairly broad 
clinical spectrum, there are several clinical 
conditions suffered from asymptomatic form to 
presenting conditions accompanied by severe 
respiratory failure that require treatment in the 
Intensive Care Unit (ICU), mechanical 
ventilation assistance for multiorgan 
manifestations. Paucisymptomatic infections 
show several symptoms. The main symptoms 
reported were fever, cough, dyspnea, headache, 
sore throat and rhinorrhea to pneumonia. 
Pneumonia as manifestation of serious 
infection, characterized by high fever, cough, 
and bilateral infiltrates on chest radiograph. 
There are no specific clinical features that can 
be relied upon to differentiate Covid-19 from 
other respiratory viral infections due to the lack 
of specific symptoms. Respiratory droplet 
(splash) and airborne (airborne) transmission 
are the main routes of transmission of Covid-
19, besides that it can also be transmitted 
through person-to-person contact by 
paucisymptomatic patients and also by 
asymptomatic patients (World Health 
Organization, 2020) 
Until now, there has not been a single 
drug therapy specifically recommended and 
confirmed to be effective and safe for Covid-
19, as we know that this disease is still quite 
new. Because it is known that the cause of 
Covid-19 is an infecting virus, so the curative 
therapy used for Covid-19, namely mostly 
broad-spectrum antiviral drugs as an alternative 
that has the potential to cure Covid-19. 
However, all these alternative medicines for 
Covid-19, both those used in Indonesia and in 
various other countries, are still in the form of 
trial and error until now. 
Currently, the drugs used for patients 
infected with Covid-19 still refer to the use of 
drugs during the Middle East Respiratory 
Syndrome (MERS) and Severe Acute 
Respiratory Syndrome (SARS) outbreaks 
several years ago. Several studies have shown 
that these drugs were quite effective at the time 
of the past epidemic to treat MERS and SARS. 
Until now, Indonesia itself has not received 
specific drug recommendations in dealing with 
Covid-19, which is relied on only drug 
preparations that are still available (Cai et al., 
2020). 
Reusing available drugs is one of the 
fastest ways to get Covid-19 treatment in an 
emergency (Aris et al., 2020). The prevalence 
or the overall number of Covid-19 cases is 
increasing from time to time, cases of death that 
sometimes decrease but suddenly increase 
often occur. However, in addition to cases of 
death, it turns out that many patients infected 
with Covid-19 can still be cured. 
Based on the above background, the 
formulation of the problem in this literature 
study is the use of any drugs that have become 
alternatives for therapy in current Covid-19 
patients. 
 
MATERIAL AND METHOD 
 
This research is a descriptive study with 
a literature study method through journal and 
document searches conducted from September 
2020 to June 2021. The data used is in the form 
of literature based on inclusion and exclusion 
criteria. The inclusion criteria include journals 
published in the last 5 years (2016-2021), types 
of clinical trial journals, randomized clinical 
trials and original journals, types of research 
journals with single or combined alternative 
drugs that have been used by Covid-19 patients 
to date. and types of journals that have data on 
clinical trial results. The data obtained were 
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collected and tabulated based on the literature 
review mapping. The tabulation contains the 
name of the author, year of publication, the 
method used and the results of the research 
which will then be analyzed and concluded. 
 
RESULTS AND DISCUSSION 
The results of the literature review on 
alternative medicines for Covid-19 can be seen 
in the table below: 
 

























This multicenter randomized 
controlled study stated that none 
of the patients in the Favipiravir 
arm required ventilation (p = 
0.129). Based on these results, 















A shorter mean viral clearance 
time was found in the Favipiravir 
group (4 days) versus the control 
group (11 days), P < 0.001). The 
Favipiravir group also showed 
significantly improved chest CT 
scans compared to the control 
group. Favipiravir showed better 
therapeutic activity in Covid-19 
in terms of clinical improvement 





Beigel, et al. DOAJ, 
November 
5, 2020. 
Final Report Open Label and Randomized 
Clinical Trial with 1,062 patients 
randomized (541 to Remdesivir 
and 521 to placebo). Patients on 
remdesivir had an average of 10 
days of recovery time compared 
to 15 days of placebo patients. In 
an analysis using a proportional 
probability model with an eight-
category ordinal scale, patients on 
remdesivir were more likely to 
experience clinical improvement 
than those receiving placebo. 
Result data show that Remdesivir 
is better than placebo in 
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Randomized open-label trial 
comparing two groups namely 
standard treatment + Remdesivir 
group and standard care non-
Remdesivir group, it was stated 
that on day 14 of treatment, 
74.4% of patients in the 
Remdesivir group had recovered 
while only 59.0% in the non-
Remdesivir group. So it was 
stated that standard treatment 
with additional therapy of 
Remdesivir had a faster healing 
activity compared to the group 
that was only treated with 











Rodrigo et al.  ClinicalTria
ls, April 





This clinical trial study was 
conducted with asymptomatic to 
mild-moderate telemedicine. The 
result data showed that 412 
patients used treatment with 
Hydroxychloroquine and 
Azithromycin and 224 patients 
refused the drug (control group). 
The need for hospitalization in 
the group with Azithromycin was 








Patients admitted immediately 
after a Covid-19 diagnosis 
received HCQ + AZM or HCQ 
alone, or AZM alone. The 
mortality rate in patients with 
HCQ + AZM at 21 days was 
22.5%, 18.9% in patients with 
HCQ alone and 10.9% in patients 
with AZM alone. However, these 
results need to be confirmed by 
further randomized studies. In 
conclusion, there are several 
arguments in favor of the 
potential effectiveness of AZM in 
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SARS-CoV-2 infection, including 
its antiviral activity and 
immunomodulatory effects. 
7. The Clinical 








19 Pneumonia  





Observational Study Of 60 
Covid-19 positive hospitalized 
patients 19 confirmed (≥18 years) 
in Hospital ward, Iran. The results 
of oxygen saturation (SpO2) and 
body temperature changed for the 
better in patients receiving 
regimen I compared to regimen 
II, changes in the two regimens 
were not clinically different. 
However, the findings showed a 
significant difference from the 
mean duration of hospital stay in 
regimen I indicating a shorter 
duration. 
8. The Use of IV 
Vitamin C for 
Patients with 
Covid-19 





The inpatient mortality rate in this 
trial was 12% with an increase in 
intubation and mechanical 
ventilation of 17.6%. We noted a 
significant reduction in 
inflammation, including ferritin 
and D-dimer, and a trend toward 
a decrease in FiO2 requirement 





C in Patients 
with Covid-
19. 





The main results obtained were a 
decrease in mortality and the 
number of patients admitted to 
the ICU. The secondary outcome 
was an increase in SpO2 and an 
overall improvement in clinical 
symptoms in Covid-19 patients in 
the hospital. 
10.  Role of  











This study shows that a 
significant negative correlation 
has been observed between 
average vitamin D levels and 
cases of Covid-19. Several 
studies have shown a role for 
vitamin D in reducing the risk of 
respiratory tract infections. 




Urban Health. Vol.3 No. 1 (2021) 
However, evidence is still 
lacking. Therefore, further testing 
of cohort studies is still needed. 
11. The effect of 
Vitamin E 
and Vitamin 













Covid-19 patients were divided 
into two groups: the intervention 
group (n=38) and the control 
group (n=34). Both groups were 
given oral vitamin C. The results 
obtained where 7.89% of the 
intervention group (3 people) and 
14.71% of the control group (5 
people) experienced treatment 
failure and the rest experienced 
clinical improvement (P=0.380). 
These results show that the 
administration of vitamins C and 
E cannot be an option in the 








Shakoor, et al. Elseiver, 29 
June 2020  
Retrospektif 
Study. 
The effects of Vitamins C, D, E, 
zinc, selenium, and omega-3 fatty 
acids are quite beneficial for 
people with Covid-19 on their 
immune systems. The results of 
trials from several studies are still 
urgently needed in the hope of 




Based on the results of a review of 
reviewed journals, various kinds of drugs can 
be used for patients infected with Covid-19 at 
this time as an alternative treatment. Some of 
these studies generally aim to find out that these 
drugs are used for therapeutic reasons that are 
more beneficial than their bad effects. The 
following are drugs that have been and are still 
being used today as alternatives in the treatment 
of patients infected with Covid-19. 
 
Favipiravir 
Favipiravir is a class of antiviral drugs 
currently widely used by Covid-19 patients, 
one of the reasons is because Favipiravir targets 
RdRp on the Corona virus. RdRp is a protein 
that has an important role in the replication of 
Coronavirus in respiratory epithelial cells (Cao 
et al., 2020; Yavuz & Unal, 2020). In the 
research of Inoue et al. (2020) have also 
mentioned that Favipiravir works by selectively 
inhibiting viral RNA polymerase so that it can 
suppress replication, and has been shown to 
have antiviral effects on SARS-CoV-2. In 
addition, purine analogues have also been 
considered for the treatment of Covid-19. 
Favipiravir acts as a purine analogue that can 
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enter guanine or adenine sites and thereby 
inhibit viral replication. 
Research conducted by Dabbous et al. 
(2020) at Ain-Shams University Hospital and 
Tanta University in the period April to August 
2020, showed the results that antiviral therapy 
with Favipiravir was able to reduce virus 
eradication time. In addition, a non-randomized 
intervention study involving 80 Covid-19 
patients stated that Favipiravir showed better 
treatment outcomes in Covid-19 patients in 
terms of reducing disease severity and viral 
clearance, this supports the possible use of 
Favipiravir in the treatment of Covid -19, Cai 
et al. (2020) also mentioned that Favipiravir 
showed significantly higher improvement rates 
on chest CT scans compared to the control 
group. In addition, fewer side effects were 
found in the Favipiravir group than in the 
control group. 
Favipiravir was approved in Japan in 
2014 as a treatment for viral infections ie its 
efficacy against the Ebola virus in the Ebola 
outbreak in West Africa from 2014 to 2015. 
Favipiravir has also shown efficacy in cases of 
infection by Severe Fever with 
Thrombocytopenia Syndrome Virus (SFTSV). 
Based on this, Favipiravir is thought to have an 
inhibitory effect on viral replication on SARS-
CoV-2, considering that Favipiravir's 
pharmacological action is considered effective 
in suppressing various viral replications (Inoue 
et al., 2020). 
 
Remdesivir 
Remdesivir is metabolized to an active 
form, namely an adenosine triphosphate 
analogue which has RdRp inhibiting activity 
which causes errors in proofreading by viral 
exonucleases so that it interferes and stops the 
viral RNA synthesis process (Cao et al., 2020; 
Sisay, 2020; Yavuz & Unal, 2020). Covid-19 
patients confirmed by the Centers for Disease 
Control (CDC) in the United States, McCreary 
& Pogue (2020) stated that patients receiving 
Remdesivir showed clinical improvement, but 
patients complained of gastrointestinal 
disturbances and an increase in 
aminotransferases, so the efficacy and safety 
this drug is uncertain. 
Testing of Remdesivir by Beigel et al. 
(2020) demonstrated infection control in adult 
patients infected with Covid-19 who were 
given Remdesivir at an initial dose of 200 mg 
on the first day. The outcome data suggest that 
the investigators recommend treatment with 
remdesivir to prevent the development of more 
severe respiratory disease. 
Research by Neldi & Suharjono (2020) 
concluded that patients with Remdesivir 
experienced a faster clinical improvement. 
Based on the outcome data, the investigators 
also state that treatment with Remdesivir can 
prevent the development of more severe 
respiratory disease, lower side effects and 
lower incidence of oxygen use. 
In light of the preliminary results 
regarding Remdesivir, the Food and Drug 
Administration (FDA) issued an Emergency 
Use Authorization on May 1, 2020, to authorize 
the use of Remdesivir for treatment in adults 
and children hospitalized with suspected or 
confirmed Covid-19 infection from laboratory. 
However, given the high mortality rate despite 
taking Remdesivir, it is clear that treatment 
with antiviral drugs alone may not be sufficient 
for all patients with different diagnoses. 
 
Azithromycin 
According to (Bleyzac et al., 2020) 
Azithromycin has been shown to have 
significant antiviral properties. Its activity 
against Respiratory Syncytial Virus (RSV) has 
been demonstrated in randomized studies in 
infants. Azithromycin has shown a synergistic 
effect when given with antivirals against 
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SARS-CoV-2, or also when combined with 
hydroxychloroquine both in vitro and in several 
clinical trials. Article from Andreani et al. 
(2020) also reported a significant antiviral 
effect of Azithromycin alone without any other 
drug combination on SARS-CoV-2. The 
antiviral effect of Azithromycin is a broad-
spectrum antiviral. Azithromycin is also said to 
reduce the rate of entry of the virus into cells, 
by increasing the immune response to the virus. 
This mechanism is universally involved in the 
innate response to infectious agents, and has the 
potential to fight viruses including SARS-CoV-
2. 
Apart from the antiviral properties of 
Azithromycin, the immunomodulating 
properties of Azithromycin are also the reason 
for its use against inflammatory manifestations 
that cause lung disease. SARS-CoV-2 has been 
shown to exacerbate the inflammatory response 
of its host, causing serious damage to lung 
interstitial tissue. Patients with severe Covid-
19-associated pneumonia may exhibit a 
systemic hyperinflammatory syndrome 
referred to as a cytokine storm. Cytokine storm 
in patients with severe Covid-19, showed a 
significant increase in several pro-
inflammatory cytokines such as interleukins 
(ILY-1B, IL-2. IL-6. IL-8, IL-10, IL-17). 
Azithromycin has shown an 
immunomodulatory profile by inhibiting 
several cytokines involved in the COVID-19 




The antibiotic Levofloxacin exerts its 
bactericidal effect against gram-negative and 
gram-positive bacteria, anaerobes, 
mycobacteria and atypical pathogens. 
However, it has now become a consideration in 
the treatment of SARS-CoV-2, due to the 
immunomodulatory properties, 
pharmacokinetics, and good safety profile of 
levoflocin. (Karampela & Dalamaga (2020) 
proposed the use of Levofloxacin as an adjunct 
in treating patients with Covid-19. 
Therapeutic efficacy of Levofloxacin 
compared with -lactams, in the treatment of 
mild to moderate community pneumonia, 
where clinical success rates of Levofloxacin 
were 96% and 90% for -lactams, respectively. 
In addition, research by Scroggs et al. (2021) 
that the efficacy and safety of Levofloxacin 
have also been evaluated in patients with mild 
to moderate and severe COVID-19. 
 
Vitamin 
Vitamin D is a fat-soluble precursor of 
steroid hormones arising from exposure to 
ultraviolet B (UVB) 7-dehydrocholesterol (7-
DHC) radiation in the skin epidermis, where it 
is converted to cholecalciferol (25-OH-D) 
precursors in the systemic. Vitamin D has roles 
in various body systems, including in the innate 
and adaptive immune responses. Vitamin D 
also promotes the differentiation of monocytes 
into macrophages and also increases the 
production of superoxide, phagocytosis, and 
destruction of bacteria. Some results from 
studies are still unclear, therefore, vitamin D 
supplementation is only recommended to 
increase immunity against Covid-19 (Shakoor 
et al., 2021). Several clinical and 
epidemiological studies regarding Covid-19 
and its relationship with vitamin D. In a 
randomized controlled trial with 5660 subjects, 
vitamin D supplementation was sufficiently 
shown to reduce the risk of respiratory disease 
(Ali, 2020). 
In addition, vitamin E and selenium are 
also major components of antioxidant defense. 
It has been noted, that there is a correlation 
between selenium levels and Covid-19 cure 
rates in various provinces in China. Vitamin E 
and selenium both act through antioxidant 
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pathways to increase T cell counts, enhance 
mitogenic lymphocyte responses, increase IL-2 
cytokine secretion, increase NK cell activity, 
and, reduce the risk of infection. (Shakoor et al., 
2021). 
Vitamin C is highly recommended for 
Covid-19 patients especially those associated 
with the presence of a cytokine storm during 
Covid-19 infection, clinical studies have shown 
that intake of 1 g/day of vitamin C increases the 
secretion of IL-10 by peripheral blood 
mononuclear cells. IL-10 works by a negative 
feedback mechanism with IL-6 and controls 
critical inflammation in Covid-19. Vitamin C 
has also been shown to play a role in secondary 
sepsis and pneumonia in Covid-19 (Shakoor et 
al., 2021). According to a study by (Hiedra et 
al., 2020) that has identified 17 patients who 
were confirmed positive for SARS-CoV-2 
through nasopharyngeal swab PCR. The patient 
was given intravenous vitamin C as part of the 
Covid-19 treatment. Analysis using a paired T 
test revealed significantly lower levels of D-
dimer and ferritin after treatment with vitamin 
C and no side effects directly related to vitamin 
C administration were noted. This test also 
states that for the time being the use of 
intravenous vitamin C is quite safe and feasible 
in patients with Covid-19 with moderate to 
severe disease. 
 
The use of available drugs as an 
alternative for Covid-19 patients is one of the 
efforts of the government and health workers in 
dealing with the emergency conditions of this 
pandemic. Antiviral drugs used such as 
Favipiravir and Remdesivir refer to the use of 
these drugs in the SARS and MERS epidemics 
of several years ago which proved effective in 
some patients. In addition to antivirals, 
antibiotics are also given to Covid-19 patients 
as a supporting treatment. Antibiotics are 
usually given in combination with several 
antivirals because of their synergistic effect on 
both. The use of antibiotics does not play a role 
in treating patients directly against Covid-19, 
but is used when a secondary bacterial infection 
occurs, because some patients infected with 
respiratory viruses are usually also infected 
with secondary bacteria. In addition, some 
antibiotics also have antiviral or immunodilator 
activity such as Azithromycin, for some of 
these reasons it is possible for some antibiotics 
to become an alternative in the current 
treatment of Covid-19 patients in combination 
with several other types of drugs. As for the 
treatment of Covid-19 by antivirals and 
antibiotics, patients are also given several 
vitamins and minerals such as vitamin C, 
vitamin D and vitamin E as well as zinc. As we 
know that the body's reaction when infected 
with a virus, especially Covid-19, is that the 
body will form resistance to prevent or 
eradicate viruses that will infect. If the immune 
system is strong, the virus can be prevented 
from entering the body. However, in people 
whose immune systems are weak, the virus can 
be difficult to fight, resulting in severe 
symptoms and fatal complications. Therefore, 
Covid-19 patients are given vitamins and 
minerals because one of the roles of vitamins 
and minerals is as an antioxidant that can 
strengthen the human immune system (immune 
system). 
However, all of these alternative 
medicines in the treatment of Covid-19 are still 
in the form of trial and error, there has not been 
a single drug that has been specifically 
confirmed to be a safe and effective Covid-19 
drug, so the use of these alternative medicines 
must be given by parties who authorities such 
as doctors accompanied by strict supervision 
assisted by other health workers, so as not to 
cause things that are not desirable. 
 
CONCLUSION 
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Based on the review and amalgamation 
of several literatures, it can be concluded that 
the drugs used as an alternative treatment in 
patients infected with Covid-19 that have been 
scientifically proven based on several literature 
studies include, Favipiravir, Remdesivir, 
Azithromycin, Levofloxacin, and supporting 
nutrition namely vitamin C, vitamin D, vitamin 
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